KindlyMD (NASDAQ:NAKA) CEO Purchases $25,180.16 in Stock

August 21, 2026 by InsiderTrades.com

Key Points

CEO David Bailey purchased 4,918 KindlyMD shares at an average price of $5.12, investing $25,180.16 and increasing his ownership to approximately 3.18 million shares.
KindlyMD shares opened at $6.30 after rising 4%, but the company remains highly unprofitable, reporting a quarterly loss of $6.65 per share and negative net margins exceeding 1,000%.
Analyst views are mixed: TD Cowen issued a $17 price target and Buy rating, while other firms maintained or raised Sell ratings. The stock carries a consensus Hold rating with an average target of $22.33.

KindlyMD, Inc. (NASDAQ:NAKA - Get Free Report) CEO David Bailey bought 4,918 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were bought at an average cost of $5.12 per share, with a total value of $25,180.16. Following the completion of the transaction, the chief executive officer owned 3,180,394 shares in the company, valued at $16,283,617.28. The trade was a 0.15% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

KindlyMD Stock Up 4.0%

NAKA opened at $6.30 on Friday. KindlyMD, Inc. has a twelve month low of $3.33 and a twelve month high of $432.40. The company has a fifty day moving average of $4.48 and a 200-day moving average of $7.24. The stock has a market cap of $112.77 million, a PE ratio of -0.18 and a beta of 15.95.

KindlyMD (NASDAQ:NAKA - Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($6.65) earnings per share for the quarter. The company had revenue of $35.87 million during the quarter. KindlyMD had a negative net margin of 1,067.93% and a negative return on equity of 63.45%. Sell-side analysts anticipate that KindlyMD, Inc. will post -11.31 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of KindlyMD in a research report on Friday, August 7th. Wall Street Zen raised KindlyMD to a "sell" rating in a research report on Saturday, May 23rd. Finally, TD Cowen raised their price objective on KindlyMD from $1.00 to $17.00 and gave the company a "buy" rating in a research note on Monday, July 27th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $22.33.

Check Out Our Latest Stock Report on NAKA

Key Stories Impacting KindlyMD

Here are the key news stories impacting KindlyMD this week:

Positive Sentiment: CEO David F. Bailey bought 4,918 shares at an average price of $5.12, investing approximately $25,180. The purchase increased his direct ownership to 3.18 million shares and may signal confidence in the company’s long-term prospects. SEC insider ownership filing
Neutral Sentiment: Maxim Group raised its EPS forecasts for several periods, including Q4 2026 to a loss of $0.48 per share from $0.60, Q1 2027 to a loss of $0.76 from $0.87, and Q2 2027 to a loss of $0.74 from $0.88. These revisions indicate expectations for somewhat smaller losses in those quarters, although KindlyMD remains unprofitable.
Negative Sentiment: Maxim lowered its Q3 2026 EPS forecast to a loss of $0.49 from $0.43 and reduced its Q4 2027 estimate to a loss of $0.43 from $0.41. More significantly, its FY2027 forecast was cut to a loss of $2.12 per share from $1.44, pointing to weaker expected profitability over the full year.

Hedge Funds Weigh In On KindlyMD

Several institutional investors have recently modified their holdings of NAKA. Virtu Financial LLC bought a new position in KindlyMD in the 4th quarter valued at $151,000. J. Derek Lewis & Associates Inc. bought a new position in shares of KindlyMD during the 4th quarter valued at approximately $167,000. Truist Financial Corp purchased a new stake in KindlyMD in the fourth quarter worth $176,000. Waddell & Associates LLC purchased a new position in shares of KindlyMD during the 4th quarter valued at $201,000. Finally, Invesco Ltd. bought a new position in KindlyMD during the fourth quarter worth about $211,000.

KindlyMD Company Profile

(Get Free Report)

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.